SUCCESS

FC Barcelona have lost both of their starting wingers thanks to injuries picked up by Lamine Yamal and Raphinha.

Bravo host Andy Cohen called the “Summer House” reunion leaks, which appear to depict a heated confrontation about a viral dating scandal, “disgusting and illegal.”

The Justice Department passed an investigation of Fed Chair Jerome Powell to the Fed’s own inspector, which could clear a confirmation path for Kevin Warsh.

It’s funny how you barely think about healthcare companies until you actually need them. And what we would all want to see at such times is a simple, smooth checkup and the quiet efficiency. Not long ago, though, Wall Street was worried about UnitedHealth (UNH), with rising costs and pressure on margins weighing on sentiment. Then came the first-quarter 2026 earnings report, shifting the narrative and prompting Morgan Stanley to raise its price target. To me, it feels less like a bold call and more like the market is catching up to a strength that never really left.UnitedHealth Group (UNH) didn’t just beat expectations on April 22, 2026. It beat them in the places that mattered most. Just exactly where investors were looking. Shares ended the day up 7%. That’s one of the clearest single-session signals that a turnaround story is beginning to find its footing.”We are continuing to help simplify and modernize health care for the people and care providers we serve, bringing greater value, affordability, transparency, and connectivity,” said UNH CEO Stephen Hemsley.”The print represents a strong start to ’26 and sets a positive tone for MCOs. We expectmomentum can continue as UNH continues to execute and build credibility. Reiterate Top Pick.” Morgan Stanley said.Morgan Stanley raises UNH stock target after strong earningsMorgan Stanley moved quickly after earnings, raising its price target on UnitedHealth Group (UNH) from $375  to $395, while maintaining its “Overweight” rating and Top Pick status.The move followed a stronger-than-expected first-quarter performance that shifted investor sentiment.UnitedHealth Group’s Q126 earnings release results:First-quarter 2026 revenues of $111.7 billion, up from $109.6 billion in the year-ago quarter (up 2%)Earnings of $6.90 per share; adjusted earnings of $7.23 per shareMedical care ratio of 83.9%, down from 84.8% in Q1 2025 Cash flows from operations of $8.9 billion, or 1.4 times net incomeFull-year 2026 EPS guidance raised to $18.27 per share from $17.772027 EPS: $20.95 (from $20.45)
Source: UnitedHealth Group First Quarter 2026 Results
Shares rose about 7% following the report, reflecting renewed confidence in the company’s recovery story.The medical loss ratio improvement is the number that matters most to managed care investors, and UNH delivered it. Per Morgan Stanley’s note, the favorable ratio was aided in part by prior-year development and a softer flu season. Meaning the second quarter, with full claims data visibility, will provide a cleaner read on the underlying cost trend by product.Related: Morgan Stanley names UnitedHealth a “Top Pick”Optum Health was the other critical proof point. The division’s first-quarter EBIT handily beat expectations, according to Morgan Stanley, offering early evidence that operational investments made in the second half of 2025 are beginning to convert into measurable results. Clinical reviews increased 50% in UNH’s West region, and skilled nursing admissions fell 35% year over year in the first month of the new care navigation approach, according to the MS’s note.Morgan Stanley says UNH is clearly moving in the right directionMorgan Stanley sees this as a key differentiator. In its first-quarter update, the company outlined a clear strategy. To deploy AI across administrative and clinical operations with an expected 2:1 financial return, and many programs paying back within 12 to 18 months. According to MS, the near-term ROI stands out in healthcare, where tech investments often take years to show results.Several initiatives are already delivering impact. Avery, a generative AI chatbot for UnitedHealthcare members, is reducing administrative friction and improving user experience. Optum Real, an AI-driven claims platform, is cutting manual adjudication costs by 76%, according to MS note. Related: Morgan Stanley adjusts RTX price target after earningsAmbient AI is helping physicians and nurses automate clinical documentation at scale, while AI-enabled self-service at Optum Rx has reduced call center volumes by 25%, MS’s note confirms.All internal AI development is being funneled through Optum Insight, building a proprietary pipeline that UNH plans to commercialize externally. Morgan Stanley views this untapped AI potential as a meaningful upside not yet reflected in consensus estimates, with an investor day in the second half of 2026 seen as a possible catalyst.Morgan Stanley’s UNH target and 2027 earnings reveal somethingMorgan Stanley’s revised price target of $395, up from $375, is grounded in a sum-of-the-parts analysis that values each of UNH’s major business segments separately against comparable peer multiples, according to the firm’s note.

Morgan Stanley raises its price target on UnitedHealth Group (UNH) from $375 to $395.

Morgan Stanley revised UNH’s earnings estimates as follows:2026 adjusted EPS estimate raised to $18.27 from $17.772027 adjusted EPS estimate raised to $20.95 from $20.45Price target of $395 implies 18.9 times the firm’s 2027 EPS estimateEven after the 7% single-session move, UNH shares were trading at just 13.7 times Morgan Stanley’s 2028 EPS estimate of $25.34. Well below the stock’s five-year and ten-year historical forward price-to-earnings averages of 15.8 times and 15.2 times, respectively, according to Morgan Stanley.The more aggressive scenario in Morgan Stanley’s illustrative 2027 earnings bridge points to potential upside of 22% to the bank’s own estimates and 27% to consensus, if management executes against its stated margin targets, yielding a broad illustrative 2027 EPS range of $21.10 to $25.63, per the firm. That range doesn’t incorporate incremental AI-driven savings that could materialize on top.More Health Care:If your Medicare plan was canceled, do this nowHealth care costs are the wild card in year-end tax planning22 million Americans hit by ACA health insurance cliff after vote failsManagement also reiterated confidence in its long-term margin targets across key segments, according to Morgan Stanley’s note, including Optum Health margins of 6% to 8%, Medicare Advantage improvement toward the high end of the 2% to 4% target range in 2027, and modest Medicaid margin improvements beginning next year.For you who have been waiting for evidence that the UNH recovery is more than narrative, the first quarter of 2026 just provided it.Related: UNH stock just did something to the Dow Jones you rarely see

QuantumScape (QS) stock jumped about 9% after earnings, but the reaction says more about shifting expectations than a breakout quarter.What moved the stock was a clearer step into manufacturing, early signs of commercial diversification, and the first real hint that the company’s model can generate revenue before full-scale battery sales begin.Management’s message to investors is simple. The story is shifting toward real-world manufacturing and to a broader, partner-driven commercialization model.Progress will take time, but there were many exciting developments this quarter.Early billings test the partner modelQuantumScape reported $11.0 million of customer billings in the first quarter of 2026, including ecosystem-related billings, and ended the quarter with $904.7 million of liquidity.The revenue is small compared to the company’s $4.5 billion market cap, but it shows that partners are willing to pay during the development phase.That supports the company’s capital-light model and suggests commercialization may not be entirely dependent on future battery sales.Investors now need to understand the quality of these billings, including how much is recurring versus tied to one-time ecosystem activity, and whether it can scale alongside customer programs.If the revenue proves repeatable, it could help offset development spending.OEM expansion reduces reliance on VolkswagenQuantumScape is starting to broaden its commercial base. In addition to Volkswagen and PowerCo, the company still has two joint development agreements with top-10 global automakers, and one additional top-10 OEM has moved from evaluation into joint development.This marks the company’s first real step into industrial production and changes the shape of the investment case. For years, QuantumScape effectively had one strategic backer, one presumed launch path, and a single point of concentration risk from its anchor partnership with Volkswagen. A broader JDA base gives the company more than one route to commercial validation.Trending Tech Stocks:Oracle adds $100B in market cap on major announcementJPMorgan has stark message on Qualcomm stockAnalysts rerate Taiwan Semiconductor stock after earningsIf multiple top-tier OEMs stay engaged as manufacturing advances, the market might start to treat QuantumScape’s technology as broadly relevant rather than strategically sponsored.Still, the next test is whether those programs move beyond technical diligence into program-specific milestones that signal real budget, platform, and timing decisions.

Eagle Line marks QuantumScape’s shift from lab validation to real-world manufacturing, with the focus now on reliably scaling production.Andriy Onufriyenko via Getty Images

Eagle Line shifts QS into manufacturingQuantumScape reached an important milestone in Q1 2026, completing installation of its automated Eagle Line, starting the system, and producing initial QSE-5 cells.This marks the company’s first real step into industrial production. The focus now shifts from lab results to whether QuantumScape can manufacture cells consistently at scale.The next key checkpoint will be the company’s second quarter, when management expects a production ramp in its QSE-5 cells. Investors will be watching uptime, throughput, and yield to judge whether the process can support qualification work with Volkswagen’s PowerCo and other partners.Execution here remains the core risk because the company is still spending heavily ahead of meaningful product revenue. QuantumScape has guided to a fiscal 2026 adjusted EBITDA loss of $250 million to $275 million and capex of $40 million to $60 million. Until Eagle Line produces qualification-ready output, investors are still funding scale-up on faith.What could push QS stock higherEagle Line ramps up with strong yield and uptime, turning validation into real qualification progress.OEM deals move from JDAs into defined programs or commercial discussions, broadening the customer base.Customer billings becoming recurring, supporting the partner model and easing funding pressure.Successful QSE-5 qualification, improving visibility, and supporting future supply or licensing deals.What could break the QS thesisManufacturing struggles emerge with yield or uptime, delaying qualification and pushing out timelines.Cells fail to perform at scale, limiting relevance with automotive customers.JDAs stall in evaluation or billings staying one-time, weakening demand signals.Losses continue without shipment progress, increasing dilution risk and signaling delayed commercialization.QuantumScape key takeawaysQuantumScape is beginning to transition from a research story into an early-stage industrial company. The launch of its Eagle Line, expanding OEM relationships, and initial customer billings all point to a business that is slowly moving toward commercialization.That said, manufacturing scale, customer conversion, and revenue quality will determine whether recent progress turns into a viable long-term business.Related: Morgan Stanley has a message for ServiceNow investors

“Between layoffs and AI taking over lower-level data work, I’m not sure jumping ship for a big raise makes sense.”

A filing Thursday said the lawsuit rehashes events already settled in court and seeks damages for losses caused by internal misconduct.

“The portfolio has grown, but I can’t help feeling that it hasn’t grown as much as it could have.”

Celebrity childcare expert Nanny Connie weighs in on Gwen Stefani’s ex Gavin Rossdale’s co-parenting comments and shares how to prioritize your children post-divorce.

ChatGPT Image 2.0 suggests that AI image generation is evolving into visual reasoning and verifiable AI, with implications for the future of physical intelligence.